Skip to main content
SpringerLink
Log in

Pergolide: treatment of choice in Restless Legs Syndrome (RLS) and Nocturnal Myoclonus Syndrome (NMS). Longterm follow up on pergolide

  • Short Communication
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Summary.

Pergolide has proven significantly superior to L-dopa plus peripheral decarboxylase inhibitor in short-term therapy of RLS/NMS. We now first present long-term follow-up sleep data showing its lastingly good effects after averagely 517 treatment days.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Göttingen, Federal Republic of Germany, , , , , , DE

    J. Staedt, H. Hünerjäger, E. Rüther & G. Stoppe

Authors
  1. J. Staedt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Hünerjäger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Rüther
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Stoppe
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Accepted December 15, 1997; received November 5, 1997

Rights and permissions

Reprints and permissions

About this article

Cite this article

Staedt, J., Hünerjäger, H., Rüther, E. et al. Pergolide: treatment of choice in Restless Legs Syndrome (RLS) and Nocturnal Myoclonus Syndrome (NMS). Longterm follow up on pergolide. J Neural Transm 105, 265–268 (1998). https://doi.org/10.1007/s007020050055

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s007020050055

Search

Navigation